A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Open Access
- 1 October 2000
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 11 (10) , 1309-1312
- https://doi.org/10.1023/a:1008393010472
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)British Journal of Cancer, 1999
- Chemotherapy for advanced pancreatic cancer: It may no longer be ignoredAnnals of Oncology, 1999
- Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumorsAnnals of Oncology, 1998
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Activity of gemcitabine in patients with advanced pancreatic carcinoma: A reviewCancer, 1996
- No standard treatment is available for advanced pancreatic cancerEuropean Journal Of Cancer, 1995
- Cytotoxicity and Antitumor Activity of 2′,2′-Difluorodeoxycytidine (Gemcitabine)Cancer Investigation, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Reporting results of cancer treatmentCancer, 1981